Human malarial disease: a consequence of inflammatory cytokine release by Clark, Ian A et al.
BioMed  Central
Page 1 of 32
(page number not for citation purposes)
Malaria Journal
Open Access Review
Human malarial disease: a consequence of inflammatory cytokine 
release
Ian A Clark*1, Alison C Budd1, Lisa M Alleva1 and William B Cowden2
Address: 1School of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT 0200, Australia and 2John Curtin School 
of Medical Research, Australian National University, Canberra, ACT 0200, Australia
Email: Ian A Clark* - ian.clark@anu.edu.au; Alison C Budd - alison.budd@anu.edu.au; Lisa M Alleva - lisa.alleva@anu.edu.au; 
William B Cowden - william.cowden@anu.edu.au
* Corresponding author    
Abstract
Malaria causes an acute systemic human disease that bears many similarities, both clinically and
mechanistically, to those caused by bacteria, rickettsia, and viruses. Over the past few decades, a
literature has emerged that argues for most of the pathology seen in all of these infectious diseases
being explained by activation of the inflammatory system, with the balance between the pro and
anti-inflammatory cytokines being tipped towards the onset of systemic inflammation. Although not
often expressed in energy terms, there is, when reduced to biochemical essentials, wide agreement
that infection with falciparum malaria is often fatal because mitochondria are unable to generate
enough ATP to maintain normal cellular function. Most, however, would contend that this largely
occurs because sequestered parasitized red cells prevent sufficient oxygen getting to where it is
needed. This review considers the evidence that an equally or more important way ATP deficency
arises in malaria, as well as these other infectious diseases, is an inability of mitochondria, through
the effects of inflammatory cytokines on their function, to utilise available oxygen. This activity of
these cytokines, plus their capacity to control the pathways through which oxygen supply to
mitochondria are restricted (particularly through directing sequestration and driving anaemia),
combine to make falciparum malaria primarily an inflammatory cytokine-driven disease.
Background
The mechanism of the disease caused by Plasmodium falci-
parum, arguably the pathogen that causes the most human
suffering, has been hotly debated for many decades.
Clearly, rational adjunct therapy depends on getting this
right. For over twenty years the central debate has come
from two apparently opposing camps. One champions
the mechanical hypothesis, based on the concept of insuf-
ficient oxygen reaching vital organs, and the other the
cytokine hypothesis, in which excessive release of pro-
inflammatory cytokines are the primary driving force of
disease and death. The former concept stresses the
uniqueness of the pathophysiology of falciparum malaria
compared to that of other severe systemic infectious dis-
eases, whereas the latter sees malaria as having fundamen-
tally the same basis as these other conditions, with the
adhesive property of parasitized erythrocytes giving it no
more than a distinctive flavour.
Critical analysis of the mechanism of falciparum malarial
disease would not have been possible without the seminal
work of Peter Mitchell [1,2], who identified mitochondria
as the ATP-generating powerhouse of aerobic cells, and
thus of all aerobic organisms. Among the doors this
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opened was the opportunity to understand severe infec-
tious disease by seeing it through the perspective of these
organelles. This review largely discusses the relative contri-
bution to disease processes of mitochondria being pre-
vented from getting enough oxygen, and being able to use
all the oxygen that reaches them, and the combined effects
of these two influences. This includes blood flow restric-
tion in microvessels by parasitized red cells that adhere to
endothelial walls (sequestration), the potential restriction
to oxygen supply that is unique to falciparum malaria. As
discussed below, the broader literature is consistent with
the view that sequestration during severe disease is not a
passive event that is simply an amplification of what
occurs early in infection and in tolerant individuals, but
one in which location and avidity of adherence, and,
therefore, pathogenic effects, are controlled by inflamma-
tory cytokines.
Despite advances in understanding diseases clinically very
similar to falciparum malaria in terms of inflammatory
cytokines, enthusiasm for the mechanical obstruction
hypothesis seems at least as strong as ever [3-5]. Although
much literature now demonstrates dependence of the
mechanisms of poor oxygen delivery on excess inflamma-
tory cytokine release, even the most recent members of the
vaso-occlusion school [5] still see the cytokine theory of
disease as an alternative to be argued against rather than
as an essential component of their own disease model.
Hence it is timely to bring together an update of the evi-
dence why cytokines are regarded as so central to this dis-
ease. In particular, it seems warranted to summarize how
broadly the harmful influences of the inflammatory
cytokines are now known to extend. By introducing con-
cepts in infectious disease in general, and then moving to
the particular case of falciparum malaria, this review
expands on these functionally interconnected conse-
quences of excess production of inflammatory cytokines.
Systemic infectious diseases and inflammatory 
cytokines
There is now remarkably widespread acceptance that
cytokines such as TNF and interleukin-1 (see "cytokine
storm" in Google) are the essential mechanism of sys-
temic disease caused by infectious agents. Indeed, one
would be hard pressed to find an alternative explanation
now current for the anorexia, tiredness, aching joints and
muscles, fever and sleepiness that patients experience in
any systemic infection, including both vivax and falci-
parum malaria. Neither is it disputed that exacerbated
release of these same mediators is the best current line of
investigation for the mechanism of severe and life-threat-
ening illness, such as sepsis [6] and influenza [7]. The dif-
ficulty, confined to falciparum malaria, is to get its broad
acceptance in a research community that has traditionally
seen its disease as unique, mechanistically separated from
other infectious conditions by the presence of sequestered
parasitized red cells often seen in certain intravascular
locations at autopsy. To some researchers sequestered par-
asites are still necessary and sufficient for illness from fal-
ciparum malaria to occur, and to cause fatality [4,8].
Much of this section will include parallels between
malaria and similar diseases caused by other pathogens,
and basic research done on the effects of inflammatory
cytokines on normal cells. It also recounts, for the present-
day audience, the malarial origin of this concept of disease
pathogenesis.
Intra-erythrocytic death of haemoprotozoa, the original 
link of TNF to disease
Nearly thirty years ago, ignorance of accepted malaria wis-
dom, in a London tumour/virology lab where this
attribute was universal, allowed a novel tumour-oriented
interpretation to be put on the observation that the non-
lethal mouse parasite, Babesia microti, was killed by the
immune system in circulating red cells [9]. This also hap-
pened in some species of malaria parasites with which it
cross-protected. Encouragement that this phenomenon
was worth pursuing came from the Guy's Hospital group,
then at the top of the malarial immunity tree, who
observed the same unexpected and puzzling phenome-
non when they challenged malaria-immunized rhesus
monkeys [10].
Of particular concern for the then official Guy's dogma
(malarial immunity operates through a specific antibody
focussed on the merozoite surface, adopted unquestioned
by other major vaccine groups), even unrelated parasites
died en masse inside red cells when previously immunized
monkeys were challenged [11]. In their view this could
offer an explanation of why some monkeys had high lev-
els of antibody expected to be protective, yet failed to
resist a challenge infection [11], while others with little or
no anti-merozoite antibody were immune [12]. A report
from the US told a similar tale [13]. Clearly, some power-
ful influence beyond specific antibody, and inconvenient
for mainstream thinking on immunity and vaccine devel-
opment, was reproducibly occurring.
Tumour necrosis factor (TNF), the prototype 
inflammatory cytokine
The observation that pre-treatment with the Bacillus Cal-
mette-Guérin (BCG) strain of Mycobacterium tuberculosis
controlled a subsequent infection with any of several
strains of babesia or malaria in mice (no antibody, para-
sites dying in red cells, not phagocytes) was fortuitously
timed with the publication of the first paper on TNF [14].
This allowed us, in collaboration with these New York
tumour researchers, to propose novel roles for TNF in
immunity and disease pathogenesis in malaria and sepsis
[15,16]. In summary, through linking the protectiveMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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capacity of agents such as BCG with the degree to which
they sensitised to bacterial lipopolysaccharide (LPS) it
came to be realised that the pathology of LPS toxicity (and
subsequently that of rTNF) and Plasmodium vinckei infec-
tions in mice were largely identical, cytokine-mediated,
events. As noted in a contribution to Brian Maegraith's
1988 Festschrift Proceedings [17], the cytokine approach
gave teeth to his inflammation-based arguments on
malaria disease of forty years earlier [18].
As reviewed in 1987 [19], this experience with mouse
babesiosis and malaria provided the insight that this anti-
tumour mediator arguably had roles in both cell-medi-
ated immunity (CMI) and the pathogenesis of infectious
disease in general. As well as malaria, this concept was rea-
soned in 1981 to explain the mechanism of typhoid [15],
sepsis in general [16], and viral diseases in 1989 [20], and
it eventually spread across all acute infectious diseases
(see [21] for a recent review). For example, within a few
years it began to dominate the sepsis literature [22,23],
and the virulence of different strains of influenza, a dis-
ease that is a standard clinical misdiagnosis for imported
malaria, has now been expressed in terms of their capacity
to induce TNF [24]. While still engendering strong oppo-
sition from some malaria researchers [4,25], these ideas
have been readily accepted by scientists working on bacte-
rial, rickettsial or viral diseases. A broad literature across
infectious disease now describes inflammatory cytokines
as having a beneficial role in host defence, but being
harmful to the host if produced excessively. Indeed, the
acceptance and applicability of this concept is now gen-
eral enough for its biological evolution to be an inde-
pendent subject for research [26].
Once neutralizing anti-TNF antibodies became available
for human use, they were tested by others for efficacy
against malarial parasites and disease. Unfortunately a
central tenet of the concept (that the pro-inflammatory
cytokines that cause disease are the same mediators that,
in lower concentrations, are responsible for the innate
immunity that controls parasite growth – see also tubercu-
losis etc. in next paragraph) was not adequately consid-
ered. TNF has been shown to inhibit a mouse malaria
parasite in vivo [27], and Plasmodium falciparum in vitro,
provided white cells to generate the next down-stream
mediator, possibly nitric oxide [28], were present [29].
This is consistent with findings in human subjects [30].
Thus it is not surprising that anti-TNF antibody, by remov-
ing inhibitory pressure from the pathogen, can enhance
the disease in falciparum malaria [31], as shown five years
earlier in human sepsis [32].
The broad relevance of these malaria-origin concepts in
immunity and disease is best illustrated by noting the con-
sequence of passive vaccination against TNF for Crohn's
disease and rheumatoid arthritis, now a large-scale rou-
tine treatment [33]. Its practical success puts the relevance
of these pro-inflammatory cytokines in human inflamma-
tory disease beyond doubt, and the major side effect (pre-
existing or acquired tuberculosis, salmonellosis, or listeri-
osis becoming fulminant) nicely demonstrates its rele-
vance to CMI against many pathogens. It is unlikely to be
coincidental that all three that flare are on our list of
organisms that protected against haemoprotozoan para-
sites, causing intra-erythrocytic death, and priming mice
for TNF production [34,35]. Evidently the host was setting
up a cell-mediated response that would protect against
these organisms. Being non-specific in nature, it also pro-
tected against haemoprotozoa as well. From this reason-
ing  Coxiella burnetii, a crude extract of which was an
extremely good protectant [36], and primer for TNF (E.
Carswell, pers. comm.) will also predictably flare if anti-
TNF is given, long term, to an arthritis patient harbouring
this human pathogen.
The inflammatory cytokines as a group
In this text, TNF is used as a term of convenience to desig-
nate the pro-inflammatory cytokines as a whole. Other
cytokines, such as lymphotoxin (LT), interleukin-1 (IL-1),
interleukin-6 (IL-6) and soluble Fas ligand (FasL) serve
similar functions. In passing, it warrants noting that the
term TNF-alpha, while still common, has been obsolete
ever since LT ceased being referred to as TNF-beta and
reverted to its original name, allowing TNF to do the
same. Although the literature connecting the pro-inflam-
matory cytokines other than TNF to malaria [37-40] is as
yet much smaller than that for TNF, this does not imply
that their potential for understanding this disease is corre-
spondingly minute. A TNF superfamily of 19 members
signalling through 29 receptors has more recently been
described [41]. Many of these mediators induce other
cytokines and enzymes that add to the inflammatory cas-
cade. For example, TNF induces migration inhibitory fac-
tor (MIF) [42,43], and TNF, IL-1 beta and LT generate the
inducible form of nitric oxide synthase iNOS [44]. Anti-
inflammatory cytokines such as IL-10, IL-4, and trans-
forming growth factor-beta (TGF-beta), also play active
roles, and an imbalance between these and their pro-
inflammatory counterparts often determines outcome in
disease. Some tens of thousands of publications on
inflammatory cytokines and systemic inflammatory and
other disease now exist.
The pro-inflammatory cytokines most closely investigated
in malaria, such as TNF, usually act as homeostatic agents,
but can cause pathology if produced excessively. A
recently defined example is MIF (see above paragraph),
belonging to an ancient gene family, with structural
homologues in bacterial organisms. As an indication of
the broad relevance and complexity of these cytokines andMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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their interactions, MIF is also induced in mammals by E.
coli lipopolysaccharide [42], staphylococcus toxic shock
toxin, and streptococcal pyrogenic toxin A [45]. Whether
this is direct, or via the TNF they induce, appears not to
have been ascertained. Likewise, MIF can act directly,
through TNF, or in synergy with it, in generating anaemia,
as discussed below. It is, as noted above, TNF-induced,
and remarkable for several reasons, one being that its
description 40 years ago [46,47], began the concept of
what are now called cytokines. Ten years later, and long
before MIF was realised to have functions other than
migration inhibition and pathogenicity in sepsis (which
its inhibition suppresses, in a realistic model, most
impressively [48]), it was the first cytokine described in a
malaria infection [49]. A few years after its rediscovery as
a homeostatic glucocorticoid antagonist [50,51], it has
become central to understanding malarial anaemia, as
discussed below. It is also increased in malarial placentas
[52].
Cytokines such as TNF and IL-1, both increased in a wide
range of systemic inflammatory diseases, including falci-
parum malaria, can induce a late-onset, but long-acting
wave of a cytokine termed the high mobility group box 1
(HMGB1) protein, which prolongs and amplifies inflam-
mation [53,54]. This molecule, previously known for sev-
eral physiological functions, now shows great promise as
a therapeutic target in sepsis, in that countering it after the
onset of illness has been reported to protect well in exper-
imental sepsis [55,56]. HMGB1 has been shown to be
increased, in proportion to degree of illness, in serum
from African children infected with falciparum malaria
[57]. Like TNF, HMGB1 has roles in other inflammatory
diseases [58], reaffirming malaria's position within their
ranks. The malarial context of HMGB1 is reviewed more
fully elsewhere [21].
TNF, a tool to determine the nature of malarial toxin
The idea of malarial disease being caused by parasites
releasing a toxin is even more venerable than that of vaso-
occlusion, since it is based on a report by Golgi in 1886
[59], in which he noted onset of fever and rigors at a pre-
dictable short interval after the regular shower of new par-
asites escape from bursting red cells. These principles were
much discussed in the first decade of the 20th century
[60]. Clearly, something like this was needed to explain
how tissue not invaded by the parasite was nevertheless
damaged during falciparum malaria. Examples are sites
such as the adult kidney and lung, where dysfunction can
be catastrophic, yet sequestration never obvious, and
often absent. The toxin idea lay fallow for many decades,
not helped, in hindsight, by the underlying assumption
that toxicity arose directly from a parasite product, in the
manner of tetanus toxin.
The proposal that malarial products were not harmful in
themselves, but only through causing the infected host to
harm itself through generating toxic amounts of mole-
cules that, in lower concentrations, inhibit growth of
malarial parasites, gave the toxin concept new impetus
[15,16,19]. These papers predicted that the nature of the
malarial product that triggers illness could be defined
through its ability to induce release of TNF from mamma-
lian cells. A group in London did much work along these
lines in the late 1980s and early 1990s [61,62], and con-
cluded it was closely related to phosphotidylinositol (PI)
[63]. Others extended this argument to the glycosylated
form of this molecule (GPI) [64]. The original proposal
that malarial toxin operates through inducing generation
of TNF and related cytokines was greatly strengthened
when immunizing mice against GPI and then infecting
them with one of the mouse malaria parasites protected
against certain pathology that TNF causes on injection
[65]. Indeed, this study reports having established that
GPI appears sufficient and necessary for the induction by
malarial parasites of host pro-inflammatory responses in
vitro. The field has been well reviewed recently [66], with
these authors and others expressing doubts about the wis-
dom of vaccinating against GPI to prevent malarial dis-
ease [21,66,67]. As noted some years ago, the need for
sufficient TNF to allow immune activation to proceed nor-
mally during infections is plausibly why this potentially
lethal mediator has survived 300–500 million years of
evolution [68]. However, despite recent reaffirmation of
the GPI/cytokine/disease concept [69], the group that first
suggested that GPI was the main TNF inducer in malaria
appear to have recently [25] changed their disease model
to one that eliminates a requirement for inflammatory
cytokines. In view of GPI having been identified through
its capacity to induce pro-inflammatory cytokines, it
would have been remarkable to chance upon a molecule
that induces these mediators, yet mimicks their actions in
their absence. Clarification awaits a more detailed report.
Breadth, and acceptance, of the cytokine concept of 
disease pathogenesis
The extensive parallels that exist between the sepsis and
malaria literature can be viewed from the perspective of
the wide range of functionally-important inflammatory
cytokines present in the circulation in both conditions
(Table 1). This strengthens the view that the two diseases
operate through very similar mechanisms. Nevertheless, a
group working with African children has recently advo-
cated that in order to understand falciparum malaria dis-
ease one must return to the pre-cytokine era. They
evidently still espouse the idea that local vaso-occlusion
uniquely sets the organ pathology of this disease apart
from others with which it is clinically confusable, in par-
ticular sepsis [3-5,70]. Since the failure of treatment with
corticosteroids to ameliorate severe cerebral malaria hasMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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been used as evidence against cytokine involvement [4], it
warrants recalling that MIF, known to be high in this cir-
cumstance [71], antagonizes glucocorticoids [72], and
nitric oxide (noting iNOS is also high [71]) inhibits glu-
cocorticoid binding to its receptor [73]. Moreover, this
data rationalizes the failure of corticosteroid as a treat-
ment.
Analogy with other diseases is still an under-exploited
tool in malaria. The original interest in TNF as a possible
mediator of both innate immunity and disease pathogen-
esis in infectious disease came from analogies between the
ability of BCG to protect against both tumours and intra-
erythrocytic protozoa [9]. When introducing the excess
inflammatory cytokine concept in 1981 [15], a common
case for malaria, gram-negative bacteria and the Jarisch-
Herxheimer reaction, all of which withstood the test of
time, was argued by analogy. As reviewed recently [21],
the range of infectious diseases that come under the sys-
temic inflammation umbrella now extends beyond bacte-
rial diseases to those caused by rickettsias, protozoa other
than malaria, and viruses. Moreover, increased circulating
levels of TNF and functionally similar cytokines have been
measured in the serum very soon after onset of illness in
virtually all those infectious diseases in which it has been
sought. In addition, essentially all of the signs and symp-
toms involved in the clinical confusability of malaria and
other causes of fever were inadvertently reproduced dur-
ing the era when rTNF was being injected in volunteers as
an antitumour agent [74,75]. This includes headache,
fever and rigors, nausea and vomiting, diarrhoea, ano-
rexia, myalgia, thrombocytopaenia, immunosuppression,
coagulopathy and central nervous system manifestations,
all of which have a literature on a mechanism through
inflammatory cytokines. The rate, timing and intensity of
cytokine (pro- as well as anti-inflammatory) release will
vary in different disease states, and also between individ-
uals, and provide them with somewhat distinctive clinical
pictures, but the fundamentals remain. The clinical pat-
terns generated are remarkably close, in that, at least in
some populations, clinical features cannot predict a diag-
nosis of malaria from other causes of fever [76].
The principle extends beyond infectious diseases. A
number of non-infectious states fit this pattern, with
excessive release of pro-inflammatory cytokines produc-
ing a systemic inflammatory response. As in malaria and
sepsis, metabolic acidosis [77,78], hyperlactataemia
[79,80] and encephalopathy are seen in tissue injury syn-
dromes such as heatstroke, trauma, and burns. As
reviewed [21], all of these conditions are ripe for an expla-
nation in terms of HMGB1, liberated from the nuclei of
damaged tissue [81], setting the scene for a broad range of
inflammatory cytokine release. Iatrogenic cytokine release
syndromes, such as the side effects of OKT3 therapy [82],
and acute graft versus host disease reaction [83,84] can
also exhibit these changes, including a reversible enceph-
alopathy. In both of these conditions the relevant pro-
inflammatory cytokines are produced excessively, and
where tested (side effects of OKT3 therapy [85], and acute
graft-versus-host disease reaction [86]), prior exposure to
neutralizing antibody directed against TNF prevents ill-
ness.
As with much research on neutralizing antibody to TNF,
this outcome does not imply that TNF is more important
than, for example, IL-1 in this context, since anti-IL-1 anti-
bodies have rarely been tried. Blocking IL-1, and indeed
IL-1 and TNF simultaneously, are in their infancy, but
show promise [87,88]. Likewise, research into the disease
aspects of LT, present in falciparum malaria, and relevant
to the mouse model of cerebral malaria, is relatively
ignored, largely through difficulty of obtaining reagents.
Additional strong evidence for inflammatory cytokines
and falciparum malaria being functionally intertwined
comes from studies on variation in the human genome in
Africa [89-91]. It is now accepted that falciparum malaria,
historically the major fatal endemic disease in much of
this continent, is associated with polymorphisms of these
pro-inflammatory cytokines and iNOS, which are induced
in this disease. Not surprisingly, sepsis and meningococ-
cal disease have a similar literature [92,93]. Like any other
DNA trying to survive, that of humans uses trial and error
to adapt itself to its surroundings, leaving a trail of evi-
dence as it does so.
In summary, illnesses arising from excessive systemic pro-
duction of inflammatory cytokines include not just
malaria and sepsis, but many more infectious, and non-
infectious, diseases. Insights gained by recognizing the
value of argument by analogy across this wide spectrum
have been immense, and the general concept is now so
firmly entrenched that, as noted earlier, its influence on
the evolutionary effects of infectious disease is a research
Table 1: Some changes common to systemic inflammatory 
states in general, including sepsis and falciparum malaria
TNF, IL-1, iNOS and IFN-gamma, MIF, IL-10 and HO-1 raised
gamma-delta T cells raised
MRP8 (S100A8) and MRP14 (S100A9) raised
Procalcitonin raised
HMBG1 raised
ICAM, VCAM and p-selectin raised
insulin resistance
hyperlactataemia
hypoglycaemia
metabolic acidosis
hyponatraemia
coagulopathy
thrombocytopaenia
decreased red cell deformabilityMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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topic in its own right [26]. It would, therefore, be most
unexpected were the illness of falciparum malaria, so clin-
ically confusable with other infectious diseases, and
known to generate the same inflammatory cytokines as
they do, to arise from an unrelated mechanism [5,25].
Mitochondria unable to use available oxygen, a 
primary effect of inflammation
Inflammatory cytokines reduce ability of mitochondria to 
use oxygen
One of the many actions of the cytokines responsible for
systemic inflammation is to disable oxidative phosphor-
ylation within mitochondria. This is reflected in the
hyperlactataemia commonly seen in severe infectious dis-
ease, and correlating with outcome. This is not to suggest
that oxygen supply and its utilization are not often limited
simultaneously, and interact. Indeed, if toxin is replaced
by its downstream consequence (the effects of pro-inflam-
matory cytokines) such interaction was proposed for
malaria by Meleney over 60 years ago [94].
Both sepsis and malaria researchers have shown that
injecting TNF, the prototype inflammatory cytokine,
increased in both diseases, causes hyperlactataemia
[95,96], and blood lactate levels in severe malaria have
proved to correlate closely with levels of both TNF and
interleukin-1 [97]. Nevertheless, it is fair to say that sepsis
researchers, without the tradition of a primary role for
sequestration to defend, have been more receptive than
malariologists to the systemic inflammatory explanation
for altered carbohydrate metabolism, and more readily
pursued it. Thus, they were more open than most of their
malaria counterparts for the insights of the early 1990s,
when newer techniques demonstrated that oxygen ten-
sion in tissues was actually increased (not decreased, as
the literature predicted) in septic rats [98], patients [99],
and pigs [100]. This implied an inability of mitochondria
to utilize oxygen, forcing glycolysis to compensate, as best
it can, for the energy deficit. The next insights came from
groups who developed the cytokine-induced mitochon-
drial dysfunction model of disease [101-103] and, thus,
provided an inflammation-based explanation for a shut-
down of aerobic glycolysis, a consequent increased rate of
glycolysis, and thus lactate production, metabolic acidosis
and cellular energy depletion. In any disease with high
levels of inflammatory cytokines this mimics poor oxygen
supply. An important difference, however, is that the
effects of the nitric oxide through which mitochondrial
shutdown largely operates are reversible [104,105],
whereas frank hypoxia, through vaso-occlusion, as evi-
denced by the stroke literature, is less so. Thus, the former,
not the latter, is consistent with the marked reversibility of
metabolic comas [106], a term advocated [21,107] to
include human malaria.
This approach to understanding energy balance in sepsis
has been followed successfully on a number of cell types,
including hindlimb skeletal myocytes, gut wall cells, and
hepatocytes. The wide range of tissues in which these con-
cepts have been demonstrated adds to the arguments on
systemic origins of lactate in sepsis and malaria. For exam-
ple, inflammatory cytokines have been shown to cause
contractile dysfunction [108,109] and also energy deple-
tion [110,111] through effects, often mediated through
induced nitric oxide [109,112], on cardiac muscle. Like-
wise, in diaphragmatic skeletal muscle there is evidence of
cytokine-induced nitric oxide [113,114] and oxygen-
derived free radicals [115] combining to form peroxyni-
trite [116,117] and this causing dysfunction of mitochon-
dria in myocytes, leading to energy depletion and thus
muscular contractile failure. The outcome here is to
reduce the patient's ability to counter acidosis by blowing
off CO2.
An additional pathway through which the inflammatory
cytokines may reduce oxygen consumption is through
peroxynitrate (OONO-), a product of NO (from iNOS
induced by these cytokines) and superoxide, overactivat-
ing poly(ADP ribose) polymerase-1 (PARP-1) [118]. This
can deplete cellular stores of NAD+, and efforts to resyn-
thesise it can deplete ATP as well (reviewed in reference
[119]). Moreover, NAD+ is essential for glycolysis, so its
depletion can be expected to impair glycolytic input into
mitochondria. These concepts were reviewed in depth in
a malaria context a few years ago [107].
Mitochondria starved of oxygen, a secondary 
effect of inflammation
This section summarizes the ways in which inflammatory
cytokines indirectly limit the supply of oxygen to cells,
and thus further reduce the capacity of their mitochondria
to generate ATP through oxidative phosphorylation.
There are good arguments from the basic literature that
they may do so through directing sequestration towards
organs that are particularly oxygen-sensitive. Being a new
concept in the malarial world, this literature is examined
here in some detail. In addition, anaemia, cardiac insuffi-
ciency, or insufficient circulating volume (see below, and
Figure 3) can all be driven by inflammatory cytokines.
Again, infectious disease in general is outlined before
focussing on the particular case of falciparum malaria.
Inflammatory cytokines cause blood elements to adhere to 
endothelium
It is well accepted that upregulation by inflammatory
cytokines of adhesion sites on endothelial cells invites
susceptible circulating blood elements to attach to the
inner wall of blood vessels. In many diseases, including
malaria, this includes activated leukocytes and platelets,
both of which play important roles in promoting proco-Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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agulant activity. For example, in malaria this activity is
seen on circulating monocytes [120] and placental macro-
phages [121], and the thrombin so formed enhances
adhesion by increasing expression of CD36 on platelet
surfaces [122].
Platelets and leukocytes
Platelets and leukocytes have been reported to adhere to
endothelium in viral [123-125], bacterial [126,127] and
protozoal infections, including the cerebral vasculature in
paediatric falciparum malaria [71,128]. In particular,
aggregated monocytes are a striking feature in malarial
placentas [129], and a less dramatic finding in cerebral
vessels [130], where they and the nearby endothelial cells
stain strongly for iNOS [71]. These adhering elements can
set up local foci of inflammation, generating more inflam-
matory cytokines (eg TNF in placentas [131]), including
inflammatory cascades initiated by HMGB1 released from
the adhering activated platelets [132]. Since HMGB1
increases are associated with severity of falciparum
malaria [57], this could account for the potentiating
effects of platelets reported in an in vitro model of
endothelial activation by P. falciparum [133]. Along with
the effects of systemic inflammation, these local inflam-
matory foci contribute to potentially fatal pathology,
including loss of endothelial integrity, in infectious dis-
eases in which circulating inflammatory cytokine levels
are sufficiently increased. Notably, the range of complica-
tions seen in falciparum malaria, including coma, can
therefore develop in sepsis [134], influenza [135], and
sometimes vivax malaria [136,137], which show evidence
of a high systemic inflammatory response, but have no
possible involvement of sequestering parasites.
Parasitized red cells, an additional circulating adherent element in 
falciparum malaria
Although falciparum malaria shares with conditions such
as severe bacterial disease much evidence for endothelial
activation (eg adherence molecules [138,139] and circu-
lating endothelial microparticles [140,141]) and its con-
sequences (eg platelet and leukocyte adherence, above), it
is distinguished from them by the presence of another
obvious adherent object – erythrocytes containing mature
parasites. From the biology of the erythrocytic phase of P.
falciparum, vascular sequestration (endothelial adher-
ence) of parasitized red cells, somewhere in the circula-
tion, is inevitable for roughly the last half of the 48 hr
erythrocytic cycle. Thus mature erythrocytic forms of the
parasite are rarely seen in peripheral blood smears. This
adherence was first noted in autopsy samples in the 19th
century [142], and fuelled the widely (but not universally;
see below) held view that much of the illness and pathol-
ogy of this disease needed little explanation other than
that offered through consequential impairment of micro-
vascular flow. Thus, through the decades a common
thread in proposals to explain falciparum malaria disease
has been a primary role for tissue hypoxia caused by vaso-
occlusion by parasitized red cells. The presence of coma,
hyperlactataemia, hypoglycaemia, and metabolic acido-
sis, all three consistent with a patient being forced to rely
on anaerobic glycolysis for energy production, have
encouraged this viewpoint. As summarized earlier,
cytokine-induced cytopathic hypoxia can also explain
these phenomena.
Microparticles in systemic inflammatory diseases
Microparticles are an intriguing component of the inflam-
matory system. First described in 1967 [143], they are a
heterogeneous group of small membrane-coated vesicles
released from many types of cells upon their activation or
apoptosis, but differ from apoptotic bodies. They retain at
least some functions of their cell of origin, which can
include platelets, endothelial cells, and various leuko-
cytes. Triggers for their release include TNF [144], and
they are increased in the circulation in systemic inflamma-
tory states such as sepsis and trauma [145,146], as well as
inducing inflammatory cytokine release themselves [147].
Along with cytokine increases, endothelial activation and
the activation and adhesion of platelets and leukocytes,
microparticles provide further evidence for a common
pathophysiology of sepsis, trauma, and malaria
[140,148,149]. While microparticles enhance the general
inflammatory activity in these circumstances, and their
exploration within the context of malaria is novel, evi-
dence that they are likely to prove to be a key to control-
ling malarial disease, any more than other inflammatory
conditions in which they act as markers of severity, is so
far lacking.
The interaction between cytokines and sequestration
Arguments against a primary role for sequestration in falciparum 
malaria illness
As noted earlier, sequestration is common in certain tis-
sues of fatal cases of falciparum malaria. Nevertheless, a
primary (ie prior to cytokine increase) harmful vaso-
occlusive role for sequestered red cells containing para-
sites does not, in our view, withstand close scrutiny. As a
simple practical example, it requires the pathophysiology
in patients equally ill from uncomplicated falciparum
malaria and vivax malaria to be quite different. Parallels
between vivax malaria and the outcome of injecting TNF
into human volunteers [75,150], and increased levels of
this and functionally-related cytokines in vivax patient
sera [151] plus the non-sequestering nature of the parasi-
tized red cells, are consistent with cytokines being suffi-
cient to cause the illness of vivax malaria. This includes
the occasional, but well documented, coma (see below).
Logically, therefore, these cytokines are sufficient to
explain uncomplicated falciparum malaria, a condition
notoriously difficult to separate clinically from vivaxMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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malaria [76]. This is consistent with occlusive parasitized
red cells becoming an essential part of pathogenesis only
when falciparum disease becomes more severe, and para-
sitized erythrocytes start to favour physiologically sensi-
tive areas such as the cerebral vasculature. Alternatively,
the total number of parasites, sequestered or otherwise,
may, through the cytokine concentrations they generate,
be what counts.
The erythrocytic life cycle dictates that sequestration is
inevitably present before the onset of illness or in malaria
tolerant individuals, yet no information seems available
on it taking any particular anatomical pattern in these
people. Newer technology involving expression of luci-
ferase by a defined stage of the life cycle, to date applied
only to a mouse model (where it revealed intriguing
results that warrant reading closely [152]), would be
impractical in man. However, an indirect appreciation of
the avidity, if not the location, of P. falciparum sequestra-
tion in asymptomatic, malaria-tolerant individuals (usu-
ally not even fever, yet parasite densities overlapping
those seen in severe illness) comes from work done in
Mali [153], in which blood smears were made three time
a day, usually at 6 hr intervals, for 12–13 days. Some 3000
blood smears were examined. Fluctuations in parasite
density between consecutive smears often proved to be
massive and abrupt, and the authors concluded that such
change could come only from mirror-image changes in
sequestration rate, not through parasite multiplication.
Transitory disappearance of parasites from the peripheral
blood occurred at least once in all infected individuals (63
of 79 subjects). Such slide negativity was of short dura-
tion, unrelated to the cycle of trophozoite maturation,
and attributed to dramatic increases in sequestration of
existing parasites. To our knowledge this rapid oscillation
between circulation and sequestration is not reported dur-
ing untreated malarial illness. On this evidence, avidity of
sequestration is lower in malaria-tolerant individuals
than in patients, suggesting different controlling influ-
ences, with sequestration in the former group, but not in
the later, being independent of inflammatory cytokines.
At autopsy, brain is often a favoured site of sequestration,
but whether this preference occurs before coma onset, or
develops while coma is progressing, has not been deter-
mined. Marked brain sequestration at death has not been
a universal observation, and, as summarized by Maegraith
[18], reports have accumulated since the 1920s on a mis-
match, at autopsy, between cerebral sequestration and
coma. Such evidence is still being presented [71], as dis-
cussed below. Impaired consciousness can occur in a
range of systemic inflammatory states, being present in
certain viral and bacterial diseases as well as malaria. Thus
regarding parasite sequestration as a necessary mecha-
nism for falciparum malarial disease ignores its close clin-
ical and pathological similarity, in terms of metabolic
changes and organs affected, to other diseases that also
can cause impaired consciousness, but lack parasitized red
cells. These conditions are now accepted to be systemic
inflammatory states [76]. As summarized below, the
broader literature is consistent with our novel proposal
(below) that, in addition to the above post-sequestration
activity of inflammatory cytokines, these mediators will
have earlier determined, during severe illness, where most
sequestration occurs.
For some time most adherents of the traditional seques-
tration-based view of falciparum malaria disease have
accepted what they regard as secondary roles for inflam-
matory cytokines in falciparum malaria disease [154]. By
these tenets, sequestration at sensitive sites, such as brain
capillaries, leads to higher local concentrations of these
cytokines near sequestered parasitized red cells, since
these are the source of the parasite material that triggers
their release, and endothelial cells and leukocytes are
commonly their source. The importance of the site of
sequestration to disease severity is thereby amplified,
involving both vaso-occlusion and secondary cytokine
effects, such as increased blood-brain barrier permeability
[155]. This as a plausible aspect of the relationship
between sequestration and inflammatory cytokines in fal-
ciparum malaria, but the concept outlined below is pro-
posed here to be their major interaction in falciparum
malaria.
Influence of inflammatory cytokines on organ distribution of 
sequestration
By far the bulk of the literature arguing for occlusion-
induced pathology in falciparum malaria concerns its
documentation in the brain [156] and placenta [157] in
sick individuals, and it is timely to consider why these
sites are favoured. Equally, why are these the main sites
where monocyte accumulations occur? The following
explanation seems highly plausible, and is testable. In
brief, it suggests that sequestration favours the brain when
circulating concentrations of TNF are high (ie when the
patient is ill), but not before onset of illness, or in malaria
tolerant individuals. The absence of mature forms on
blood smears from these two groups implies that the
capacity of parasitized red cells to sequester is quite
robust, but sequestration is not focussed at harmful sites
without raised inflammatory cytokines.
For over a decade there has been substantial evidence that
inflammatory cytokines (TNF the most studied) increase
expression on endothelial cells of the molecules to which
parasitized erythrocytes adhere [158-160]. Being driven
by cytokines whose detection and concentrations corre-
late with degree of illness, this increase can be expected to
operate only in moderate to severe illness, not early inMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
Page 9 of 32
(page number not for citation purposes)
infection, when TNF levels are undetectable, or in tolerant
individuals, who have been argued to be refractory to
malaria-induced TNF [161]. Blood smears confirm that
sequestration occurs in these individuals. In the next par-
agraphs it is argued that during severe falciparum illness
these cytokines (provided they have not killed the patient
beforehand) could concentrate most sequestration to the
sites familiar at autopsy.
TNF and interleukin-1 increase tissue factor expression on
endothelial cells and mononuclear cells [162], thereby
initiating pathways that generate thrombin (reviewed
recently [163]), a molecule with many roles at the cross
roads of inflammation and coagulation. When bound to
thrombomodulin, a thrombin receptor on the endothe-
lial cell surface, thrombin activates protein C, which can
degrade Factor VIIIa and Factor Va, essential cofactors in
The proposed influence of differences in thrombomodulin levels on cytokine-induced expression of adhesion molecules on  endothelial cells, and monocyte attraction, in different organs Figure 1
The proposed influence of differences in thrombomodulin levels on cytokine-induced expression of adhesion molecules on 
endothelial cells, and monocyte attraction, in different organs. (a) tissues with low endothelial thrombomodulin levels (b) tis-
sues with high levels.Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
Page 10 of 32
(page number not for citation purposes)
the activation of Factor X and prothrombin respectively
[164]. These feedbacks play a central role in keeping coag-
ulation in homeostasis.
It follows, therefore, that tissues in which thrombomodu-
lin density on endothelial cell surfaces is lowest (brain
least – indeed reported undetectable in an earlier study
[165] – placenta next least, and other organs more [166]),
will have more unbound thrombin left available for its
other functions on activated endothelium. These include
a ten-fold upregulation of adhesion molecules such as E-
selectin by TNF [167], CD36 [122], intercellular adhesion
molecule-1 (ICAM-1 CD54) and vascular cell adhesion
molecule-1 (VCAM-1 CD106) [168] and, with implica-
tions for the observed accumulation of monocytes, mono-
cyte chemotactic protein-1 (MCP-1) [169]. Moreover,
thrombin – thrombomodulin complex formation will be
low in tissues where endothelial thrombomodulin is low.
Therefore protein C activation will be correspondingly
low, and the negative feedback that controls TNF-induced
thrombin formation correspondingly weak (Figure 1a),
further enhancing concentrations of the above adhesion
molecules. Levels of a range of inflammatory cytokines,
including TNF, are high in supernatants of villous leuko-
cytes from malarial placentas [170], so these principles
should apply to the monocyte accumulations and heavy
sequestration in this organ also.
Thrombomodulin also sequesters HMGB1, making it less
available to activate RAGE (the receptor for advanced gly-
cation endproducts, shared by this cytokine [171]), so it
cannot express its full inflammatory potential [172], and
thus generate a further wave of cytokines such as TNF.
Hence a given concentration of HMGB1, a cytokine
increased in serum in sepsis [53] and falciparum malaria
[57] in proportion to degree of illness, can be predicted to
exert more pro-inflammatory influence in brain and pla-
cental vessels, where more of it is functionally available
because less of it sequesters on thrombomodulin. Unfor-
tunately the intestinal blood vessels, another favoured site
for sequestration in falciparum malaria, were not
included in either the CD36 [122] or the thrombomodu-
lin study [166]. The reverse of the arguments for brain
serve to rationalise why sequestration is rare or absent in
heart and skeletal muscle, tissues at the other (high) end
of the thrombomodulin spectrum [166], and therefore
with least free thrombin left available to upregulate
sequestration sites during TNF-induced illness (Figure
1b). For these reasons harmful sequestration is best
regarded as a consequence of increased inflammatory
cytokine generation, as well as a potential way to focus
release of these mediators at sequestration sites. In short,
differential endothelial activation induced by high levels
of circulating inflammatory cytokines could shift the
emphasis of sequestration to potentially harmful loca-
Immunohistochemical staining of the gut wall of malaria patients to detect iNOS Figure 2
Immunohistochemical staining of the gut wall of malaria patients to detect iNOS. Techniques (DAB, haematoxylin), materials 
and controls as in reference 71. Cases (a) MP6 and (b) MP21 (see Table 1 of ref. 71) are shown. Unpublished data.
(a) (b)Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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tions where, through schizogony, it could then initiate the
bulk of the next wave of cytokine release. As previously
noted for neuron function in malaria [173], nitric oxide
generated by iNOS induced by these cytokines could also
plausibly explain the small intestine intussusception seen
in most children dying with malarial coma in Malawi
[174]. Nitric oxide has an essential role in an experimental
model of this pathology [175], and iNOS is strongly
induced in the small vessels of the jejunum (Figure 2) in
this patient series.
Anaemia
As recently reviewed [176], critical illness associated with
an inflammatory response invariably causes multifacto-
rial anaemia. It has often been noted that anaemia could
contribute to poor oxygenation of tissues in malaria [177]
and there is general acceptance that it can be severe
enough to reduce supply of oxygen to mitochondria to
dangerously low levels. Thus it can be a major component
of malarial pathology. Obviously a high parasite load
indicates imminent widespread lysis, but anaemia does
not correlate with parasitaemia, and sometimes is extreme
when very few parasites are present.
Poor red cell deformability
Erythrocytes have a limited life, determined by how long
they can remain flexible enough to squeeze through fen-
estrations in specialised vessels in the red pulp of the
spleen [178]. A red cell that cannot pass this test is phago-
cytosed by adjacent macrophages, and lost. In health this
loss is balanced by erythropoiesis, and haematocrit
remains normal. Should red cells develop a premature
poor deformability they are removed from the circulation
correspondingly earlier.
Like other cells, erythrocytes stay intact by constantly
extruding Na+ in exchange for K+  through an energy-
dependant "pump" in their cell membrane that was
defined by the ability of certain digitalis gylcosides to
block it. This Na+/K+ pump fails, and intracellular Na+
accumulates in (non-parasitized as well as parasitized) red
cells during human [179] or monkey [180] malaria. These
changes in ionic content of red cells have been observed
in a sepsis model [181]. In another sepsis model [182],
erythrocyte deformability could be shown to be caused by
NO, an inhibitor of this membrane pump [183]. Since
inhibition of the Na+/K+ pump in vitro correlates with a
reduced red cell deformability plus a parallel decrease in
red cell filterability [184], any influence, such as NO
[183,185], that inhibits this pump could potentially cause
poor red cell deformability. Cytokine-induced iNOS pro-
vides a demonstrable [71] way for these changes to occur
in severe malaria.
Originally recorded in uraemic patients, poor red cell
deformability was observed in a small pilot study of
malaria patients in 1985 [186]. Soon after it was recog-
nized in sepsis [187,188], and subsequently studied in fal-
ciparum malaria with a view to understanding both
circulatory obstruction [189] and anaemia [190]. There is
good evidence that, when measured on admission, a
severe reduction in red cell deformability is a strong pre-
dictor of malarial mortality [189], but whether this is
cause and effect, or the two phenomena are simply inevi-
table co-travellers in a strong pro-inflammatory milieu, is
unclear. It seems clear that poor red cell deformability
(which affects parasitized and unparasitized red cells
equally) and dyserythropoiesis can lead to severe anaemia
in various diseases, particularly in chronic infections such
as malaria. Its presence in vivax malaria [191] implies that
its role in vaso-occlusion is less important.
Clearly, it would be useful if a shortened lifespan of red
cells through their premature loss of membrane flexibility
were compensated for by a faster rate of erythropoiesis.
Unfortunately, the inflammatory cytokines that shorten
the lifespan of the red cells also slow down their replace-
ment, as outlined in the next section. Their combined
effect on reducing haematocrit can be expected to be
rapid.
Dyserythropoiesis
Because the parasite inhabits erythrocytes, which must
burst if the parasite is to propagate, the obvious initial
conclusion was that this source of red cell loss was central
to the fall in haematocrit seen in this disease. As reviewed
nearly 60 years ago [192], this fall was soon realised to be
out of proportion to the number of red cells parasitized,
so other factors were realised to contribute. Phagocytosis
of unparasitized red cells was also recorded decades ago in
monkey [193] and human [192] malaria, and for many
years was regarded as sufficient explanation for this dis-
crepancy. Others had been investigating dyserythropoiesis
in the bone marrow of patients with falciparum malaria
[194,195] and stressed its contribution to malarial anae-
mia. A group in Oxford [196], seeking an explanation for
this dyserythropoiesis through an electron microscopy
study of bone marrow, observed sequestration of parasit-
ized red cells and argued that this caused the bone marrow
dysfunction in falciparum malaria by restricting blood
flow and thus inducing hypoxic changes. This idea proved
inadequate, however, when this same group subsequently
reported dyserythropoiesis and erythrophagocytosis in
vivax malaria, in which parasitized red cells do not
sequester [197].
Twenty-five years ago our group proposed that TNF might
cause the bone marrow depression seen in malaria [15].
Subsequently an undefined product in macrophage super-Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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natants [198], later identified as TNF [199], was found to
inhibit the growth and differentiation of erythroid pro-
genitor cells. When rTNF became available (but before it
had become technically possible to assay for this cytokine
in human serum) the dyserythropoiesis and eryth-
rophagocytosis seen in terminal Plasmodium vinckei-
infected mice were reproduced when a single injection of
rTNF was given early in the course of the infection [200].
Phagocytosis of erythroblasts in bone marrow, a phenom-
enon also reported by Wickramasinghe et al. [196,197] in
human malaria, was commonly observed [200].
Decreased erythropoiesis was subsequently reported in
mice receiving continuous TNF infusions via implanted
osmotic pumps, and increased erythropoiesis in malarial
mice after injecting neutralizing antibody directed against
murine TNF [201]. TNF-induced dyserythropoiesis has
since been confirmed in rats [202], and mice expressing
high levels of human TNF become markedly anaemic dur-
ing malaria infections [203], even though parasite num-
bers, and therefore red cell loss post-schizogony, are
considerably reduced.
The past decade has seen an expansion of this line of
enquiry into human malaria, and also the number of
cytokines, both pro-inflammatory and anti-inflammatory
[204,205] in absolute amounts and ratios [206,207], that
have been investigated in this context. It has been
extended to include other pro-inflammatory cytokines,
such as IL-12 [208] and FasL [40], and the role of the per-
sistence of production of such cytokines in the anaemia of
falciparum malaria infection has recently been examined
[209]. Suppression of prostaglandin E2 during malaria
infection has also been shown to have an important influ-
ence on these events [210].
A decade ago the mechanism of TNF-induced damage to
human bone marrow cells was argued to be nitric oxide
generated by iNOS induced by TNF [211]. More recently
attention has focussed on another cytokine, MIF, down-
stream of TNF but also induced by agents other than TNF,
as a cause of malarial dyserythropoiesis. Martiney and co-
workers [212] found that MIF was enhanced in a mouse
malaria model, and that rMIF inhibited the formation of
erythroid (BFU-E), multipotential (CFU-GEMM), and
granulocyte-macrophage (CFU-GM) progenitor-derived
colonies in vitro. Subsequently, MIF proved to be strongly
detectable by immunohistochemistry in systemic, but not
cerebral, vascular smooth muscle of fatal African paediat-
ric sepsis and falciparum malaria [71]. It has very recently
been found that sub-inhibitory concentrations of MIF
synergise profoundly with TNF and interferon-gamma in
inhibiting mouse erythroid precursor colonies [213].
These authors provide other data that greatly strengthens
the case for a major role for MIF in malarial dyserythro-
pioesis. This work provides a timely warning against the
reductionist approach to understanding the actions of
cytokines in disease, which does not reflect the in vivo real-
ity of a considerable number of these mediators being
present simultaneously. Thus the slow replacement rate of
red cells in malaria through the influence of inflammatory
cytokines is now a well-established aspect of malarial dis-
ease pathogenesis. In summary, cytokines induced by
malaria products are a major determinant of haemo-
globin deficiency, and thus the rate at which oxygen
reaches mitochondria in malaria.
Infection-induced dyserythropoiesis is not restricted to
malaria. The first awareness of it in other infectious dis-
eases appears to have been its description in HIV patients,
plausibly as a consequence of opportunistic infections
[214]. It has subsequently been observed in acute viral
hepatitis B [215], simian [216] and human [217] parvovi-
rus B19, visceral leishmaniasis [218] and dengue [219], all
conditions that are associated with increased levels of cir-
culating TNF, and doubtlessly its regulators, such as MIF.
As noted above, the effect on red cells of the combination
of a lower rate of production and accelerated destruction
can be expected to lead to severe anaemia. The literature
on both these influences on red cells underline how
widely the consequences of excessive inflammatory
cytokines impinge on disease pathogenesis, and empha-
sise the conceptual limitations imposed by regarding fal-
ciparum malaria as somehow outside the sphere of these
host-origin mediators [5,25].
Cardiac insufficiency
Cytokine-induced myocardial depression frequently
accompanies severe sepsis (see [220]). Whereas it was pre-
viously considered a pre-terminal event, it is now clear
that cardiac dysfunction, as evidenced by biventricular dil-
atation and reduced ejection fraction, is present in most
patients with severe sepsis. It has been known for some
time to be caused by soluble factor(s) released by macro-
phages exposed to endotoxin [221]. Once cloning of
cytokines occurred its activity was attributed to IL-1, then
also to TNF [222], then the two synergistically [223], and
finally to IL-6 [224], a macrophage product induced by
both of these mediators. A literature exists on these effects
being minimised by blocking MIF, which reduces the
feedback inhibition of TNF production by glucocorticoids
[225,226]. As discussed in above, excess inflammatory
cytokines have been shown to cause cardiomyocyte mito-
chondrial dysfunction. Since TNF [38], IL-1 [38], IL-6 [39]
and MIF [71] are all highly expressed in falciparum
malaria, it can be expected that these cardiac-depressing
activities would be acting in this disease as well as in sep-
sis. Evidence of this, in terms of circulating cardiac pro-
teins, has accumulated in the past few years [227,228],
although its clinical impact is yet to be evaluated. It may
be present, but its potential clinical impact is over-riddenMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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by the effects of hypovolaemic shock, as summarized in
the next section.
Poor circulating volume
Insufficient intravascular volume is ultimately of concern
in disease because, through poor perfusion, it leads to
poor oxygen supply where it matters, the microcirculation
that feeds the mitochondria within the cells that form the
tissues the capillaries pass through. The major therapeutic
option is volume resuscitation. As recently reviewed
[229], it is under the control of a number of autoregula-
tory mechanisms, and these are known to be disrupted in
sepsis. As well as the effects of changed red cell deforma-
bility, and adherence of platelets and leukocytes, as dis-
cussed above, variation in iNOS induction, leading to
more or less nitric oxide, essential for local degrees of the
vasodilation that perfusion depends on, are major con-
trolling factors.
Using a range of indicators, workers in Kenya have con-
firmed the older observation [230] that shock is not rare
in severe falciparum malaria [231], and that the haemody-
namic changes in children with severe malarial anaemia
complicated by the respiratory distress were more charac-
teristic of hypovolaemia than of biventricular failure
[232]. They have also demonstrated that while adminis-
tering albumin did not improve acidosis, it did reduce
mortality [233]. This conceptual approach has been stren-
uously questioned by others who detected only a mild fall
in total body water volume and extracellular water vol-
ume [234], as well as the relative rarity of severe hypoten-
sion in falciparum malaria compared to the shock that can
accompany trauma or sepsis [4]. However, local effects
may be much more important in falciparum malaria than
in sepsis – for example these could in part arise from
vasodilation being much more uneven in malaria than
sepsis because of patchy local foci of post-schizogony
malaria toxin release from sequestered parasites, and local
generation thus of the inflammatory cytokines that induce
endothelial iNOS [71]. It is recognized that during treat-
ment one would need to be cautious of fluid overload if
the patient displays evidence of cerebral oedema [235] or
cardiac insufficiency [236].
The detailed arguments on both sides of this debate are
beyond the scope of this review, except to note that they
are currently a major fault line between those who pro-
pose that malaria has a fundamentally similar pathophys-
iology to other acute systemic infections [21,233,237] and
those who see it as unique [238]. This issue cannot be
resolved until recognition is given to the need to research
the pathophysiology of malaria and other systemic infec-
tious states in parallel rather than, as at present, in isola-
tion.
From this and the previous section, it is not hard to visu-
alise the combined harmful effect on the patient when
systemic inflammation reduces oxygen supply to their
cells also makes these cells worse at using it. As shown in
Figure 3, the initiating pathophysiological lesion is the
onset of the systemic inflammatory response, and it is dif-
ficult, from the evidence, to envisage sequestering parasit-
ized red cells, per se, initiating malarial disease before it is
focussed to sensitive organs by systemic release of inflam-
matory cytokines. Sequestering parasitized red cells may
then, in part through locally released cytokines, exacer-
bate the illness if the patient survives long enough.
Practical consequences of these changes
Hyperlactataemia in malaria and other infectious diseases
Hyperlactataemia, a recognized marker of falciparum
malaria severity, is at the centre of controversies relevant
to the theme of this review. Its discussion requires some
basic biochemical background. The lactate anion has
complex roles in biology. Hyperlactataemia may be asso-
ciated with acidosis, a normal pH, or alkalosis [239], and
can occur in viral and rickettsial diseases [240], as well as
(see below) sepsis and malaria. In synopsis, most lactate
is generated during glycolysis, which essentially consists
of oxidising glucose, a six-carbon structure, into two three-
carbon molecules of pyruvate. This is reduced to lactate
through the action of pyruvate dehydrogenase, a reaction
that avoids pyruvate accumulating, and supplies NAD+ to
keep glycolysis going. Thus lactate can be formed as a
byproduct of glycolysis, which can occur in all metaboli-
cally active tissues and supplies ATP, albeit in small
amounts, independently of the presence of oxygen. Every
mole of glucose metabolised by anaerobic glycolysis to
carbon dioxide and water yields 4 moles of ATP, whereas
oxidative phosphorylation within mitochondria yields 32
moles of ATP. When oxygen usage falls (whether through
poor supply or poor utilisation) ATP generation falls, and
glycolysis is accelerated to compensate, as much as possi-
ble, for this energy loss. A consequence is oversupply of
the byproduct, lactate, but from a disease perspective this
is a side issue compared to insufficient ATP generation,
even though the two may correlate well. Enhanced glyco-
lysis under aerobic conditions can also increase lactate
production. The metabolic acidosis secondary to this fail-
ure of mitochondrial energy production, which high lac-
tate often accompanies, is a consequence of this energy
failure, and inevitably accompanies it in severe inflamma-
tory illnesses, including malaria and sepsis.
The body's supplies of glucose, including stores of its pol-
ymer, glycogen, are not unlimited, so when glycolosis is
enhanced for any period it sooner or later runs out of fuel.
Gluconeogenesis fills the breech as much as possible, but
it soon fails because substrate supplies are limiting [241].
These events are reflected in the hypoglycaemia that hasMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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often been reported in severe malaria [242] and sepsis
[243,244]. When seen in this context hypoglycaemia in
these diseases is no longer a primary cause of harm, such
as when driven by hyperinsulinaemia, but an inevitable
consequence of over-exuberant, typically anaerobic, glyc-
olysis.
Origin of the high circulating levels of lactate
Poor oxygen delivery to mitochondria
In the 19th century an association had been noted
between hypoxia and lactate accumulation in tissues, and
a progression of logic through the physical exercise litera-
ture [245] led to lactate levels being seen not only as a
marker for poor oxygen delivery in disease states, but also
a consequence of it, and the cause of the acidosis. For
some time hyperlactataemia has been regarded as a func-
tionally relevant marker for a poor prognosis in both sep-
sis [246] and malaria [247]. It is now well accepted that
hyperlactataemia correlates with a poor prognosis in pae-
diatric falciparum malaria in Africa [97,177,248].
Although the sepsis world now discusses several origins
for the lactate increase, including inflammation-induced
mitochondrial dysfunction [103], in falciparum malaria it
is still generally attributed to a reduced oxygen supply,
mostly through microvascular occlusion by sequestered
parasitized erythrocytes [70]. Unfortunately, the tradi-
tional conceptual approach (in which not only are acid
properties attributed to the lactate anion but lactate and
lactic acid are equated and used interchangeably) is dying
hard in the malaria world.
Recent publications [4,238] promote the traditional view
by arguing that lactate/pyruvate ratios are higher in
malaria than in sepsis (but see [249]), and can therefore
be explained only by hypoxia through vaso-occlusion
[4,70]. However, it seems difficult to envisage a mecha-
nism whereby insufficient oxygen reaching tissue mito-
chondria would generate higher lactate/pyruvate ratios
than would its poor utilisation once there. Indeed an
inadvertent positive control of mitochondrial dysfunc-
tion, seen as the side effects of treatment of HIV patients
with nucleoside reverse transcriptase inhibitors that cause
mitochondrial toxicity [250], can generate lactate/pyru-
vate ratios up to double that recently reported for severe
malaria [4,70], and as high as any value reported for the
severest adult cases in Thailand [251].
In order to test the possibility that sequestration is essen-
tial for these changes in skeletal muscle sections, tissues
previously stained for other purposes [71,252] have been
recently re-examined for adhering parasitized red cells.
Since skeletal muscle is a tissue with one of the highest
rates of oxygen consumption [253], it is predictably a
large generator of lactate when anaerobic respiration
dominates, whether triggered by oxygen insufficiency
from vascular occlusion by sequestering parasitized eryth-
rocytes or its adequate presence, but under-utilisation,
through mitochondrial dysfunction. To address the vaso-
occlusion possibility, 1–3 tissue sections from chest wall
and/or diaphragm from each of 27 previously described
[71] fatal malaria cases of African paediatric malaria were
examined blind by three observers. Negligible sequestered
parasites were observed in 24 of 27 cases (unpublished
data), including 15 displaying a 3+ or more sequestration
score in cerebral capillaries. In the light of the high throm-
bomodulin levels on endothelial cells in vessels in skeletal
muscle [166], and its implications for expression of adhe-
sion molecules (Figure 1b), this is not surprising. Unfor-
tunately, lactate assays were not performed on this patient
series. Nevertheless the high incidence of hyperlactatae-
mia in fatal cases from this same population [254] implies
that the incidence of skeletal muscle sequestration would
need to be considerably higher than observed for this
hyperlactataemia to have its origins in impeded oxygen
delivery to this main glucose-consuming organ.
Poor oxygen usage by mitochondria
The concept termed cytopathic hypoxia [103], is now con-
sidered to be a major contributor to the pathogenesis of
sepsis. This is consistent with the evidence from animal
models that neutralizing TNF prevents [255] or reverses
[256] metabolic acidosis in experimental sepsis, although
the indirect action of TNF on oxygen delivery, through its
effects on endothelial activation, and thus platelet and
leukocyte adhesion, can also be expected to contribute in
vivo. In addition, inhibiting TNF successfully treated the
metabolic acidosis of sepsis in a double blind trial in pre-
mature infants [257], and immunizing mice against GPI,
a malarial toxin selected for its capacity to induce TNF
production, inhibited metabolic acidosis in a mouse
malaria model [65]. These outcomes are equally likely to
apply in any disease in which levels of the pro-inflamma-
tory cytokines, including TNF, are raised, and metabolic
acidosis occurs. Studies on muscle ATP depletion during
severe sepsis in patient material [258] and experimental
animals [259] have provided data consistent with these
arguments. It would be most instructive to repeat these
same experiments with muscle biopsies from malaria
cases.
Since the inflammatory cytokines that cause mitochon-
drial shutdown are prominent in both sepsis and malaria
[38,39] it can be inferred that this organelle dysfunction is
an equally plausible cause of reduced ATP synthesis and
increased lactate accumulation in both diseases, corre-
spondingly diminishing the need to invoke the argument
based on parasite-induced vascular occlusion to explain
these changes in malaria. Moreover, the mitochondrial
ultrastructural damage that correlates with lowered oxida-
tive phosphorylation in a sepsis model [260] parallels thatMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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described by Maegraith in monkey malaria [261]. In
recent decades few malaria researchers have remarked on
the demonstration, by Maegraith's group, decades ago, of
the now topical inhibition of mitochondrial function in
malaria [262,263]. In our opinion these were landmark
observations that paved the way for a role for severe sys-
temic inflammation in causing the metabolic acidosis and
contributing to the raised lactate levels seen in severe
malarial disease. Indeed, in 1954 this group discussed the
concept of functional hypoxia in malaria arising from
interference with oxygen acceptance by tissue cells [264].
Hypoxia and TNF both induce HIF-1
Hypoxia-inducing factor-1 (HIF-1) is a transcription fac-
tor that regulates activation of several genes responsive to
low oxygen, including erythropoietin, vascular endothe-
lial growth factor, glycolytic enzymes, and glucose trans-
porters. These pathways need to be switched on whenever
aerobic respiration is reduced, since they are essential for
the body to generate as much ATP as it can. As evidence
that both poor oxygen delivery and its poor utilization
through the inhibitory effect of inflammatory mediators
on mitochondria produce the same functional and, there-
fore, clinical end results, it should be noted that TNF [265]
has, even in normoxic cells, the same HIF-1-inducing abil-
ity as has hypoxia [266]. This is predictable from the abil-
ity of TNF to shut down mitochondria (eg via the
reversible effect of nitric oxide on cytochrome c [104]),
the oxygen sensor that regulates HIF [267]. It provides a
plausible explanation for the accelerated rate of aerobic
glycolysis sometimes reported in sepsis [268], which can
increase pyruvate and lactate levels in the absence of
hypoxia [269].
Should cytokine-accelerated glycolysis occur under aero-
bic conditions, any resultant hyperlactataemia cannot be
expected to be associated with acidosis, since protons are
generated by ATP hydrolysis in mitochondria, and pH
remains constant. The desirability of enhancing HIF-1 in
systemic inflammatory states, in which category the pres-
ence of excess pro-inflammatory cytokine production
places malaria, has recently been reviewed [270]. MIF, a
pro-inflammatory mediator shown to be upregulated dra-
matically in a number of tissues in both severe falciparum
malaria and sepsis [271], also accelerates glycolysis [272],
so can be expected to contribute to the hypoglycaemia
and hyperlactataemia of both diseases. As with HIF-1,
both hypoxia [273] and TNF [42] upregulate MIF. Since
anti-MIF antibody prevents hypoglycaemia and increases
fructose 2,6-biphosphate in TNF (-/-) mice administered
endotoxin, MIF is argued to act independently of TNF
[42]. The relative importance and interaction of HIF-1 and
MIF in this context have not yet been examined, but these
activities of TNF and MIF nevertheless stress that an
understanding of malarial disease needs a broader vision
than simple vascular occlusion.
Metabolic acidosis
Metabolic acidosis is not a disease, but a symptom of a
serious underlying process. As recently summarized [274],
metabolic acidosis is defined as a decrease in blood pH
secondary to a decrease in the bicarbonate concentration.
The decrease in bicarbonate concentration may be sec-
ondary to an excess of acids that will consume bicarbo-
nates, reflecting the open character of this buffering
system, or to a loss of bicarbonates through the digestive
or the renal route. These authors [274] note that impor-
tance of the metabolic acidosis may be appreciated by
measuring the change in bicarbonate concentration from
the normal, or the base excess, which gives a better assess-
ment of the acid load because it takes into account the
buffering of the non-bicarbonate systems. Despite the
impression that much malaria literature gives, metabolic
acidosis is not unique to this disease, being seen in viral,
rickettsial and bacterial infections [240] as well as acute
gastroenteritis, where its prevalence is higher than in
malaria [275].
Lactate: a cause, marker, or neither in the acidosis of malaria or 
sepsis?
The notion persists in some malaria circles that excess lac-
tate accumulation causes the metabolic acidosis that cor-
relates with a poor clinical outcome, and therefore
warrants therapeutic reduction [4,276]. Accordingly,
these authors argue that lowering lactate levels with
sodium dichloroacetate (DCA), an inhibitor of pyruvate
dehydrogenate kinase, would be sufficient to ameliorate
the metabolic acidosis of falciparum malaria [4,276,277].
In our view the current literature on systemic inflamma-
Table 2: 
Influenza 
encephalopathy
Cerebral 
malaria
seizures/coma after high grade 
fever
++
metabolic acidosis + +
hyperlactataemia + +
serum TNF, IL-6, sTNFRI up + +
serum nitrite/nitrate up + +
CSF TNF, IL-6, sTNFRI up + +
multiple organ failure, sequelae + +
thrombocytopaenia + +
damage to vascular endothelial 
cells
++
brain oedema/damage to BBB + +
apoptosis in neurons/glial cells + +
evidence of active caspase-3 
(brain)
++
caspase-cleaved PARP (brain) + +Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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tory diseases does not support this. To successfully treat
metabolic acidosis DCA would need to increase oxygen
consumption so that oxidative phosphorylation takes
over from anaerobic glycolysis as the dominant ATP pro-
ducer, and the protons generated when ATP is resynthe-
sized from ADP and inorganic phosphate are re-
consumed, increasing pH to normal levels [278].
A recent editorial in Critical Care Medicine [279] has
lucidly summarized the key points of the mechanism of
metabolic acidosis in sepsis, a condition that shares sys-
temic inflammation and a range of its consequences with
severe malaria (Table 2). These authors do not accept that
lactate is the cause of the acidosis associated with hypoxia.
Instead, they note the evidence that cellular acidosis dur-
ing hypoxia, be it from limited oxygen supply or utilisa-
tion, arises from the hydrolysis of non-mitochondrial
ATP. Every time a molecule of ATP undergoes hydrolysis,
a proton is released. When oxygen is readily available, the
products of this reaction, including protons, are recycled
by mitochondria, and pH does not change. During
hypoxia, however, the mitochondrial turnover rate drops
below the rate of ATP hydrolysis, so protons are being pro-
duced faster than they can be recycled, and intracellular
pH falls once buffering capacity is exceeded. Since these
reactions are independent of lactate levels, merely reduc-
ing the level of this anion can therefore no more be
expected to increase survival rate in falciparum malaria
than it did in sepsis [280]. Indeed, it could in theory harm
comatose patients, since there is evidence that lactate
helps brain tissue survive hypoxic and hypoglycaemic epi-
sodes [281-283], and the lactate shuttle is proving to be
how astrocytes protect neurons from metabolic stress
[284]. Moreover, infusing enough lactate into patients
with severe sepsis to cause hyperlactataemia did not cause
acidosis, but an alkalosis [285].
Even when considerable lactate is generated under these
conditions, it is now evident that other anions contribute
much more than it does to the strong ion difference (SID)
that, through influencing the body's buffering capacity,
has a considerable influence on acidosis in sepsis
[286,287] and falciparum malaria [275,288]. Thus lac-
tate, while to some degree a useful marker of metabolic
acidosis in malaria and sepsis, seems not to be a cause of
it, and therefore not a worthwhile therapeutic target.
The basic biochemistry of these pathways, in which pro-
tons are consumed when ATP regeneration occurs aerobi-
cally, but accumulate, lowering the pH, when ATP
regenerates anaerobically, was elegantly set out by Dennis
in 1991 [289]. Others have noted the difficulty in separat-
ing the effects of acidosis from those of hypoxia. Since
much evidence points to hypoxic cells preferring an aci-
dotic environment [274], they question the wisdom of
unthinkingly reversing acidosis. Establishing whether
increased circulating lactate levels merely indicate a dom-
inance of anaerobic glycolysis over oxidative phosphor-
ylation in cellular energy generation, or whether it is
innately harmful because its formation generates acidosis
during oxygen-independent glycolysis, clearly has treat-
ment implications.
Effect of cytokine-induced defective respiratory muscle function on 
acidosis
The importance of hyperventilation in helping to get rid
of the excess CO2 that accumulates in metabolic acidosis,
inactivating the bicarbonate buffering system, is well
accepted in sepsis [290], and mechanical ventilation is
used, as necessary, to facilitate its removal. The decrease in
blood pH will depend on the PaCO2, which reflects the
respiratory response to the metabolic disorder. As
reviewed [274], if the metabolic acidosis is isolated and
the patient can breathe unassisted, the importance of the
hyperventilation is predictable, and simple formulas (the
most common used being: PaCO2 = 1.5 [HCO3-] + 8) give
the PaCO2 from the HCO3 value. This has a parallel in the
clear lung severe respiratory distress of falciparum
malaria, with deep stressful breathing, first described in
paediatric patients in coastal Kenya a decade ago. This
hyperventilation predicted over three times the likelihood
of a fatal outcome than did coma alone, and was recog-
nized as a consequence of the underlying severe metabolic
acidosis [236,291]. Logically this should prove to be asso-
ciated with high circulating levels of pro-inflammatory
cytokines.
This need to breath heavily for an extended period
demands much work of the muscles of the chest wall and
diaphragm. Unfortunately, the pro-inflammatory
cytokines that contribute to the acidosis also generate the
inducible form of nitric oxide synthase (iNOS) in skeletal
muscle in animal models of sepsis [292] and patients with
this condition [117]. This is associated with poor muscle
contractility, and thus a reduced capacity to self-correct
acidosis through deep breathing. There is evidence to link
this causally with inflammatory cytokine-induced nitric
oxide and oxygen-derived free radicals causing mitochon-
drial dysfunction within the muscle of the diaphragm.
This is in keeping with a similar functional role for the
strong iNOS staining (Figure 4a) in chest wall skeletal
muscle of fatal malaria and sepsis cases in African children
[71]. Diaphragm skeletal muscle (unpublished) show the
same picture (Figure 4b). Intense staining of skeletal mus-
cle for iNOS in sepsis [293] and malaria [71] is consistent
with the large difference recently found in nitrite/nitrate
levels in the same tissue between survivors and non-survi-
vors admitted into intensive care because of sepsis [258].
These samples were subsequently analysed paramagneti-
cally, and changes consistent with a decreased concentra-Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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tion of mitochondrial Complex I iron-sulphur redox
centres, which are particularly susceptible to nitric oxide,
were linked to a fatal outcome [294].
More recently, the function of mitochondria in the dia-
phragm muscle of rats treated with bacterial endotoxin,
which induces, in man as well as rat, the range of pro-
inflammatory cytokines raised in both sepsis and malaria,
has been examined in detail. A range of genes for proteins
required for the mitochondrial electron transport chain
are downregulated [295], resulting in reductions in vari-
ous key subunits of Complexes I, III, IV and V of the trans-
port chain, and a large fall in mitochondrial oxygen
consumption [296]. Energy production and thus work
ability of skeletal muscle is decreased. New data from
these workers' laboratory provides a rationale, in terms of
preventing this mitochondrial dysfunction, for the
haemoxygenase-1 (HO-1) has been reported to be greatly
increased in key tissues in falciparum malaria and sepsis
[252]. In brief, they found that administering an HO-1-
inducing agent, haemin, before endotoxin, protects mice
against endotoxin-induced mitochondrial dysfunction in
diaphragm and cardiac muscle, including failed ATP gen-
eration [297]. They note the possibility of adopting this
principle, if not this agent, in treating severe sepsis.
Malaria is an obvious extrapolation worth exploring.
In summary, lactate is an approximate, but workable,
marker for metabolic acidosis, which in turn is a good
marker for hypoxia, the primary pathophysiological
lesion in these diseases. Whether arising from (a) poor
supply of oxygen to mitochondria (through vasco-occlu-
sion, low circulating volume, anaemia or cardiac insuffi-
ciency) or (b) reduced cellular utilisation of oxygen
through mitochondrial dysfunction (in response to severe
systemic inflammation) the outcome is essentially the
same. The presence of inflammatory markers and the
nature of the illness implies that mitochondrial dysfunc-
tion is the constant, and poor oxygen delivery the varia-
ble, in a synergistic whole.
Neurological involvement in malaria
Severe falciparum malaria – more than cerebral malaria
The literature on this disease reflects the fact that by far the
most cases occur in children in tropical Africa, although
comparisons with the clinical picture in Papua New
Proposed control of pro-inflammatory cytokines over the influences that limit oxygen delivery, as well as over the capacity of  mitochondria to use oxygen Figure 3
Proposed control of pro-inflammatory cytokines over the influences that limit oxygen delivery, as well as over the capacity of 
mitochondria to use oxygen.
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Guinea, where children are said to experience a generally
milder disease, [298] have been made. Over 60 years ago
it was noted that the disease closely resembles that caused
by fulminant bacterial or viral infections [299]. The clini-
cal picture typically consists of three overlapping syn-
dromes (impaired consciousness, severe respiratory
distress, and severe anaemia), and the more of these
present the higher the mortality. This complexity has been
most clearly set out in the well-known Venn diagram
based on observations made in coastal Kenya [300]. By
using the term malaria with impaired consciousness,
rather than cerebral malaria, the review from which this
diagram is derived [300] avoids the pitfall of assuming
that the altered brain function that can occur in severe fal-
ciparum malaria requires local histologically detectable
changes that are unique to this condition. The other two
syndromes common in this disease in African children,
severe respiratory distress, an indicator of an underlying
metabolic acidosis, and severe anaemia, are discussed
below.
Cerebral vaso-occlusion and impaired consciousness in falciparum 
malaria
Cerebral malaria is certainly simpler to understand if one
operates from the premise that, as Marsh and Snow so elo-
quently put it, severe malaria equals cerebral malaria
equals cerebral microvascular sequestration [300]. Unfor-
tunately, scientific argument on this question is muted,
since publications are more readily obtained by dissecting
the mechanism of sequestration than by questioning its
importance. It is proposed here that, rather than consider
the effects of systemic inflammation and cerebral vascular
obstruction by sequestered parasitized erythrocytes as
opposing theories of cerebral malaria (as the literature has
until now), they are functionally inseparable, with harm-
fully located sequestration viewed as one of the many con-
sequences of systemic inflammation. In addition, there
are ample arguments against cerebral sequestration acting
in isolation as a major cause of the coma of falciparum
malaria.
Certainly coma can be a striking component of severe fal-
ciparum malaria, and sequestration plus accompanying
microhaemorrhages a spectacular aspect of terminal brain
histology. Yet, one without the other has commonly been
reported, and a causal link questioned. An example from
60 years ago is by Kean and Smith [301], who collected 12
cases with clinical courses of cerebral malaria, yet cerebral
vessels recorded as not being plugged. Another five cases
in which cerebral vascular plugging was present had non-
cerebral deaths.
Sequestering parasitized red cells are often an obvious his-
tological feature, so some researchers [5,8,302] continue
enthusiasm for vaso-occlusion being the prime mover of
falciparum disease, with the cytokines of systemic inflam-
Immunohistochemical staining of (a) chest wall and (b) diaphragm muscle of malaria patients to detect iNOS Figure 4
Immunohistochemical staining of (a) chest wall and (b) diaphragm muscle of malaria patients to detect iNOS. Techniques (DAB, 
haematoxylin), materials and controls as in reference 71. Cases (a) MP21 and (b) MP39 (see Table 1 of ref. 71) are shown. 
Unpublished data.
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mation reserved, at best, for justifying what are seen as
peripheral phenomena such as fever and nausea. Indeed,
the notion of the vomiting and nausea of severe malaria
being best explained by intestinal vacular sequestration is
still put forward [174], many years after TNF, the major
cytokine increased in the circulation in severe malaria,
was shown to produce these changes when injected into
volunteers [150]. To be credible as the major initiating
cause of malarial coma, any proposed mechanism has to
reconciled with the low incidence of residual neurological
deficiency in cerebral malaria survivors compared to that
seen after the archetypal cerebral vaso-occlusive state,
stroke, in which even a short period of coma predicts
severe functional loss [106]. It also needs to explain how
malaria-tolerant individuals routinely avoid coma (or
indeed illness), since sequestration of infected red cells is
a normal part of the biology of the parasite, and the para-
site density in tolerant children can be quite high [303].
Clearly, non-vasoocclusive mechanisms for malarial
coma can accomodate these two commonly reported phe-
nomena. The recent emphasis, when considering the
pathogenesis of severe illness, on total parasite load
(implying a corresponding level of malaria toxin-induced
mediators of host origin), rather than the degree of
sequestration they cause [174], is a welcome development
towards acceptance of the cytokine concept.
Human babesiosis is a haemoprotozoan tick-borne dis-
ease often associated with symptoms that are similar to
falciparum malaria [304,305]. Species that cause human
infections include Babesia microti, the mouse form of
which is functionally allied with several mouse malaria
species, in that they cross-protect and cause similar
pathology [306]. Complications in human B. microti
infection can include altered mental status, adult respira-
tory distress syndrome, renal insufficiency, disseminated
intravascular coagulation (DIC), gastrointestinal bleeding
and multi-organ failure [304,305]. These changes have
been assumed, in parallel with the tradition for human
malaria, to be caused by vascular occlusion. Since B.
microti does not sequester in mice, a recent opportunity
was taken to see if it behaved differently in tissues from a
patient infected with this parasite. Sequestration was not
observed [307]. The implications, from this single case
study (a splenectomised individual, but the pathology can
be equally complex in intact and asplenic patients
[308,309]), implies that another mechanism, such as high
cytokines [310], must be the cause of the falciparum-like
pathology of this disease. It is also appropriate to note
here that selection for degree of sequestration of Babesia
bovis, widely regarded as a parallel for the vaso-occlusive
model of falciparum malaria, did not produce parasites
that generated more virulent infections in cattle [311].
As English and co-workers have noted, the low mortality
when coma occurs in the absence of anaemia or markers
of metabolic acidosis indicates that a localised cause of
coma, such as cerebral vaso-occlusion, is very unlikely to
be a sole cause of mortality without a systemic inflamma-
tory input, and that coma in acidotic children might well
have a different mechanism than in those with brain
lesions only [312]. Nevertheless, loyality to the vaso-
occlusion explanation of malarial coma and death can be
strong, leading, in one instance, to several interpretations
of the same autopsy series [8,71,313]. One version [8] dis-
counts evidence of systemic inflammation [71] and argues
that cerebral malaria should be redefined as an autopsy-
based, cerebral sequestration-defined entity rather than,
as is usual, a clinical syndrome with the capacity to
encompass a range of mechanisms, local or systemic,
thought able to generate the same clinical endpoint
[300,314]. The need to treat ill individuals and conduct
clinical research in circumstances when patients survive,
or autopsies are impractical, ensures that the present
standard clinical definition is not likely to be displaced.
Indeed in a recent publication on microparticles [140] the
laboratory seeking to give cerebral malaria an autopsy-
based definition [8] itself reverted to the standard defini-
tion, of necessity. Final decisions on what can be learnt
from the only large African paediatric autopsy study to
date await publication of the autopsy reports from this
study, and correlation with the information already in the
literature on these cases [71,252].
If cerebral sequestration proves not to become prominent
until soon before death, might it, though present at
autopsy, have been incidental to the fatal outcome? There
is now increasing agreement [69,314,315] with insights,
now decades old [19,316], that the coma of falciparum
malaria can often be a cytokine-induced metabolic
encephalopathy. Thus, a consensus appears to be develop-
ing that, despite how technically impressive knowledge of
the mechanism of adhesion is becoming [317], the rapid
and usually complete resolution of cerebral symptoms in
most (presumably even those with cerebral sequestration)
who recover is inconsistent with a primary role for
mechanical microcirculatory obstruction. This adds to the
evidence that it seems ill-advised to regard fatal coma in
malaria-infected African children as having been caused
by malaria only when sequestration is present in brain
sections [8].
Functional evidence, in terms of reduced blood flow, has
been sought for cerebral vascular occlusion being impor-
tant in the pathogenesis of disease during falciparum
malaria, both in Thai adults [318] and African children
[319], but not found. Indeed, increase in cerebral venous
pO2 was noted at the time [318] to be consistent with an
inability to utilise the oxygen delivered, a cytokine-Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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dependent concept discussed above. Another approach
has capitalized on variation in the degree to which differ-
ent strains of parasite cause adhesion of the red cell they
inhabit. One study found no association between disease
severity and adherence to CD36, and significance for
ICAM-1 when anaemic cases are discarded [320], while
another reported a significant inverse correlation of illness
severity with both binding sites [321]. In contrast to the
traditional story, this implies that sequestration could be
associated with a less pathogenic infection. The tools to
test anti-PfEPM1 in this context have been available for
several years, and demonstrated to work in the human/
severe combined immunodeficiency (SCID) mouse chi-
meric model [322], but to our knowledge there are no
reports of them having been tested clinically.
The outcome of the recent study in African children
referred to above [71] provides a very useful window on
"pure" falciparum malaria compared to cases in which
death may have occurred sooner because of another con-
tributing factor. One third of the 32 fatal clinically-
defined cerebral malaria cases examined histologically
had little or nothing to see in the brain by way of seques-
tered parasites, monocyte clusters, microhaemorrhages, or
iNOS or HO-1 staining that would have indicated the
advent of local vascular inflammatory change at the time
of death. Some had high parasitaemias [71] and strong
gut vessel sequestration of parasitised red cells (unpub-
lished). Yet this third was clinically diagnosed as cerebral
malaria on the same criteria as were the rest, presumably
providing a modern day example of the cases described by
Kean and Smith [301]. Two of this group had severe anae-
mia, and others, on autopsy, proved to have non-malarial
changes, such as bacterial pneumonia or patchy hepatic
necrosis. These changes were judged to have contributed
to the fatal outcome, leading to an earlier autopsy, in
malaria terms, than would have happened in the absence
of this joint cause of death. As discussed [107], this group,
one third of the cases, gives an useful insight into what
may have been happening within the cerebral vasculature
of the rest of these patients, the "pure" malaria cases, after
they had become comatose, but were still some time away
from death, when cerebral sequestration, monocytes,
platelets and microhaemorrhges were present [71].
Intriguingly, these comatose malaria cases with no appre-
ciable change in their brains nevertheless showed appreci-
able systemic evidence of inflammation, as demonstrated
by the marked evidence of iNOS, MIF [71] and HO-1
[252] expression elsewhere. These systemic changes were
shared with the comatose sepsis cases in the series –
indeed there was nothing to tell them apart immunohis-
tochemically, and the depth of coma was of the same
order in both groups. The outcome in most of these cases
was likely to have been determined by the acute down-
stream effects of inflammatory cytokines, including
energy depletion and metabolic acidosis, although data
that could have provided this degree of detail was unavail-
able from these individual cases. The rest of the cases, with
a range of degrees of sequestration and evidence of sys-
temic inflammation, are discussed in detail in a recent
review [21].
From the principles that form the stroke literature, indi-
viduals with appreciable cerebral sequestration are likely
to be over-represented in fatal cases. Likewise, comatose
patients who do not develop local brain changes, includ-
ing overt sequestration, might well have a higher chance
of survival, and are thus under-represented in the fatal
comatose cases from which are drawn the histology sam-
ples that are the basis of the sequestration theory of cere-
bral malaria. Recent work on mouse cerebral malaria,
caused by Plasmodium berghei ANKA, has used new exper-
imental tools to address this question, and in a detailed
and convincing study goes against conventional wisdom,
disassociating cerebral pathology from sequestration
[152]. This research warrants being given due weight by
those advocating the relevance of this model to the pri-
mary lesion in human cerebral malaria. The next section
of this review provides examples of cytokine-induced met-
abolic encephalopathies that cast light on the coma of fal-
ciparum malaria.
Systemic inflammation, no parasite sequestration, yet still 
encephalopathy
To understand cerebral functional impairment, including
coma, in clinically defined cases of falciparum cerebral
malaria that show minimal if any sequestration on brain
sections [18,71], it warrants considering which other
infectious systemic diseases can cause a focal encephalop-
athy. In 2002, Kunze provided an excellent overview
[323] in which he discussed metabolic encephalopathies
in general under hypoxic, ischaemic, systemic (including
infectious) and toxic groupings. It seems clear that
changes occurring in falciparum malarial encephalopathy
qualify it for inclusion in several of these categories with-
out the presence of the sequestered parasites. This 2002
review provides adequate material from which to argue
that an intense inflammatory response, in the sense of a
strong systemic pro-inflammatory imbalance of
cytokines, as distinct from the traditional cellular influx,
can cause a cerebral syndrome essentially the same as that
observed in severe falciparum malaria.
Cerebral malaria caused by Plasmodium vivax
Probably the most immediately relevant of these enceph-
alopathies to a discussion on falciparum malaria (for it is
just as validly termed cerebral malaria) is the reduced con-
sciousness sometimes seen in severe vivax malaria, caused
by a parasite accepted not to sequester. For many yearsMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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such reports were dismissed as undiagnosed double infec-
tions (vivax plus falciparum), but evidence from geo-
graphical areas where falciparum malaria was not present,
plus new specific diagnostic techniques, have led to an
acceptance of the concept. For instance, in 2002 Beg col-
lected the records of 41 such cases [136], and a more
recent study described 11 such patients [137]. They exhib-
ited cerebral symptoms, renal failure, circulatory collapse,
severe anaemia, haemoglobinuria, abnormal bleeding,
acute respiratory distress syndrome and jaundice, all of
which are commonly associated with falciparum malaria.
Vivax malaria can demonstrate a strong systemic inflam-
matory response [324], but this was not examined in
these cases. Anstey and co-workers have compared a range
of pulmonary functions in vivax and falciparum infec-
tions, and concluded that a common underlying inflam-
matory mechanism was probably acting [325].
Sepsis encephalopathy
As in falciparum malaria, mental confusion and obtunda-
tion can be early signs of the sepsis syndrome, and altered
mental status is associated with a higher mortality [326].
The clinical features of sepsis encephalopathy vary from
mild confusion to coma, one study of 69 sepsis cases find-
ing 32 with severe functional changes [323]. This study
showed that in sepsis the brain fails in parallel with other
organs, and that the severity of the systemic illness, rather
than the encephalopathy per se, accounts for the outcome
in individual patients, although the brain proves to be a
sensitive indicator of severe generalised septic illness.
More recently, Morita and co-workers [327], studying 27
acute sepsis encephalopathy cases, including some assso-
ciated with influenza (see next section), found inflamma-
tory cytokines to be higher in the serum than in the
cerebrospinal fluid. They also reported that high serum
inflammatory cytokine levels at the initial stage of illness,
and the good correlation of those levels with outcome,
suggest that systemic inflammation has a significant role
in the blood-brain barrier permeability, general vascular
leakage and multiple organ dysfunctions in patients with
acute encephalopathy. Evidence of causality has been
observed in an animal model in which prior administra-
tion of a neutralizing antibody to TNF prevented the sep-
sis encephalopathy, generated through experimental
pancreatitis, a standard functional example of sepsis
[328].
Influenza encephalopathy
Probably the best documented encephalopathy which
closely parallels the changes that may occur in falciparum
malaria is the form sometimes seen in severe influenza. It
is most frequently reported in children in Japan and other
Asian countries, and provides a close functional match
indeed. As in malaria, the infectious agent is not neuroin-
vasive [329]. Seizures and coma occur after high grade
fever [330], commonly accompanied by thrombocytopae-
nia [330], and metabolic acidosis and hyperlactataemia in
severe cases (T. Ichiyama, pers. comm.). TNF, IL-6,
sTNFRI, and soluble E-selectin are increased in serum and
CSF [331,332], and serum nitrite/nitrate levels are
increased [333]. Vascular endothelial cells are damaged
[135] and multiple organ failure and neurological seque-
lae occur [334], as does brain oedema associated with
damage to the blood-brain barrier [335]. More detailed
examination of brain has revealed apoptosis of neurons
and glial cells [335], as well as histological evidence of
active caspase-3 [335], and caspase-cleaved PARP [335].
As summarized in Table 2, these changes are all demon-
strable in the encephalopathy of falciparum malaria,
implying that in this disease sequestering parasitized
erythrocytes may accompany, rather than cause, them.
The concept of cytokine-induced mitochondrial respira-
tory failure, as discussed above, is a topic of interest in
influenza encephalopathy research [336]. It is noteworthy
that circulating levels of cytochrome c, released from dam-
aged mitochondria, are increased in both sepsis [337] and
influenza encephalopathy [332], in which it has proved to
have better prognostic predictive value than do inflamma-
tory cytokines [338]. This provides a strong case for it also
being tested in severe malaria.
It is feasible, but to our knowledge not yet investigated,
that increased inflammatory cytokines might cause some
degree of poor brain microcirculation in influenza
encephalopathy, as well as some local enhancement of
inflammation, through inducing adhesion of platelets
and monocytes. Were this so, it would be reasonable to
regard such changes as pathology-enhancing accessories
after the event was under way rather than prime instiga-
tors of it. In summary, influenza encephalopathy demon-
strates that a syndrome inseparable from cerebral malaria
can occur without invoking adherent parasitized red cells.
The evidence suggests that the CM(A) group of paediatric
malaria cases [71], and well as the earlier Kean [301] and
Maegraith [18] examples, are conceptually the same as
influenza encephalopathy.
Hyperphenylalanaemia and IDO induction in systemic infectious 
diseases
Phenylalanine is an aromatic amino acid required, in con-
trolled concentrations, for the normal synthesis of various
monoamines essential for brain function. Several types of
genetic defects of phenylalanine hydroxylase or tetrahyd-
robiopterin metabolism can elevate its plasma levels to
pathological levels. If not corrected by a low phenyla-
lanine diet from an early age, chronic excess of this amino
acid can cause an encephalopathy associated with sei-
zures, and in time retards brain development and causes
various functional deficits [339]. Transient hyperphenyla-
laninaemia can be induced by endotoxin [340] or TNFMalaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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[341], so not surprisingly is a component of the various
systemic inflammatory states. For example phenylalanine
is reported to be increased (20.9-fold in CSF and 7.5-fold
in plasma) in septic encephalopathy [342]. In another
study the increase correlated with APACHE II score [343].
The same increase in severe falciparum malaria, particu-
larly in comatose children [344,345], is entirely consistent
with this condition also being another systemic inflam-
matory state, a main theme of this review. Therefore, as in
sepsis encephalopathy, a reasonable case can be made for
transient hyperphenylalaninaemia to be an additional
inflammation-associated mechanism for encephalopathy
in malaria, independent of vascular occlusion. So too, as
reviewed recently elsewhere [315], does the induction, by
inflammatory cytokines, of indoleamine 2,3-dioxygenase
(IDO), a rate-limiting enzyme in the L-tryptophan-
kynurenine pathway, which converts L-tryptophan, an
essential amino acid, to N-formylkynurenine. The obser-
vations that this also occurs in sepsis [346] and trauma
[347], also strengthen our original case [348] for organ
failure in malaria, sepsis and trauma having the same
pathophysiology.
Seizures in encephalopathies
As noted above, hyperphenylalanaemia warrants serious
consideration as a contributor to the seizures observed in
septic encephalopathy and cerebral malaria. So too does
zinc chelation by S100 proteins. Our 2003 studies on tis-
sue sections from East African children [71,252] included
a number of cases of severe sepsis encephalopathy, with-
out malaria parasites but with bacterial pathogens (eg
Escherichia coli and Salmonella enteritidis) present. Certain
tissues exhibited immunohistochemical evidence (iNOS,
MIF and HO-1) of intense systemic inflammation. S.
enteritidis is a pathogen known to alter brain function,
causing a diffuse encephalopathy, including seizures as
part of a systemic syndrome [349]. Current ideas on the
origin of septic encephalopathy, including blood-brain
barrier opening and S100B as a possible marker for the
degree of pathology, have been discussed recently [350].
S100B has also been reported to be increased in cerebral
malaria in Vietnamese adults, where it was associated with
seizures [351].
Serum and CSF Zn levels decrease during infectious dis-
eases, and this decrease is more significant in patients with
febrile convulsions [352]. Both S100B and other members
of the S100 protein family, including S100A12, are strong
chelators of zinc [353,354]. S100A12 is an IL-1 and TNF-
inducible mediator found to be increased in severe
malaria serum (M. Griffith, C. Geczy and I. Clark, submit-
ted) and detected in monocytes in cerebral vessels in falci-
parum malaria and Salmonella enteritidis sepsis (Figure 5).
Cerebral zinc homeostasis is essential for normal brain
function [355] and, of relevance to seizures, zinc induces
the spontaneous depolarising synaptic potentials that
normally dampen synaptic transmission. These potentials
can be inhibited by zinc chelation [356]. These authors
Immunohistochemical staining of cerebrum of (a) African paediatric control (MP41), (b) Salmonella enteritidis (MP12) and (c) P.  falciparum (MP6) cases to detect S100A12 Figure 5
Immunohistochemical staining of cerebrum of (a) African paediatric control (MP41), (b) Salmonella enteritidis (MP12) and (c) P. 
falciparum (MP6) to detect S100A12. Techniques (DAB, haematoxylin) as in reference 71. Antibody courtesy of Dr Carolyn 
Geczy. See Table 1 of ref. 71 for case details. Unpublished data.
A paediatric control A comatose falciparum 
malaria case
A comatose Salmonella
enteritidis sepsis case
(a) (b) (c)Malaria Journal 2006, 5:85 http://www.malariajournal.com/content/5/1/85
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note the implications of this result for understanding sei-
zures in young children with acute dietary zinc deficiency.
The concept warrants exploration in the seizures in the
encephalopathies of sepsis, influenza and malaria in
young children, since S100B and cytokine-induced S100
proteins can be expected to act like these synthetic zinc
chelators [356] and generate local areas of functional zinc
deficiency.
Inflammatory cytokines offer insights into differences 
between childhood and adult malaria
There are real differences in the nature of the disease in
children and adults. For example, severe anaemia is much
more common for a given parasite density in young chil-
dren than in older children and adults [300], and seizures
follow a similar pattern [357]. In contrast, cerebral
malaria is less common in the very young, and the pulmo-
nary and renal complications seen in adults are very
uncommon in children [300]. Moreover, children can
experience a type of clear lung respiratory distress not
reported in adults [358], implying a more severe meta-
bolic acidosis driven by the need to blow off excess CO2
and restore normal pH. This is consistent with hypogly-
caemia (from high glucose consumption feeding the
anaerobic state that is causing proton accumulation)
being a characteristic of childhood malaria more than of
adult cases.
The cytokine theory of disease provides directions that
could lead to an understanding, currently lacking, for
these age differences. For instance, generation of nitric
oxide, which has been instrumental in the Na+/K+-ATPase
inhibition thought to cause poor red cell deformability,
and thus shorten erythrocyte life span, is higher in
younger children [359,360]. Additional nitric oxide gen-
erated by a systemic inflammatory response would add to
this higher base level, reducing red cell deformability cor-
respondingly more in the very young. This could be
tested. Likewise, pulmonary and renal organ failure being
common in severely affected adults, but virtually absent
in children [300], has an exact parallel in the age differ-
ences for the inflammatory response that follows trauma
[361]. This has been explained in terms of the different
balance of inflammatory cytokines generated from nor-
mal peritoneal cells collected from children vs adults
[362,363]. There seems no reason why these data, derived
from normal human cells, should not be equally applica-
ble to any human systemic inflammatory state, including
malaria. This enhanced anti-inflammatory response of
young children can also be expected to minimize the pro-
posed focussing of sequestration during severe illness in
this age group, contributing to their low incidence of cer-
ebral malaria [300].
Conclusion
In broad terms, the essential mechanism of death in falci-
parum malaria disease is agreed by many researchers: a
functional tissue hypoxia that forces an unsustainable
dependence on anaerobic metabolism. An unresolved key
question is whether the tissue hypoxia arises (a) because
insufficient oxygen reaches the mitochondria through
either vascular occlusion from sequestered parasitized red
cells acting alone, or in combination with anaemia or (b)
because excessive release of inflammatory cytokines,
induced by malarial toxin(s), render mitochondria unable
to use oxygen to generate energy from oxidative phospho-
rylation. Although wearing contemporary clothes, this is
the same dichotomy that was present a hundred years ago.
Current basic literature suggests that inflammatory
cytokines are very much the dominant partner, having
amongst their powers the capacity to shut down bone
marrow, make red cells prematurely poorly deformable,
and channel sequestration towards certain sites, dictated
by inate local thrombomodulin concentration (Figure 1).
Thus cytokines and poor oxygen delivery should not be
viewed as alternative theories of malarial disease patho-
physiology. Instead, the latter is one of the consequences
of the former.
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